Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study by Shuxia Qin, Xuehong Wang, Sini Li, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan

Connect to this object online.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan

Connect to this object online.